2009
Pyroglutamate formation influences solubility and amyloidogenicity of amyloid peptides. A driving force in different neurodegenerative disorders?
Schlenzig D, Manhart S, Cinar Y, Willbold D, Kleinschmidt M, Hause G, Schilling St, Demuth H-U.
Biochemistry 2009, 48, 7072-7078 (Medline)
Intraneuronal pyroglutamate-Abeta 3-42 triggers neurodegeneration and lethal neurological deficits in a transgenic mouse model.
Wirths O, Breyhan H, Cynis H, Schilling St, Demuth H-U, Bayer TA.
Acta Neuropath. 2009, 118, 487-496 (Medline)
Heterologous Expression and Characterization of Mammalian Glutaminyl Cyclase Isoenzymes.
Stephan A, Wermann M, von Bohlen A, Koch B, Cynis H, Demuth H-U, Schilling St.
FEBS-Journal 2009, 276, 6522-6536 (Medline)
Developmental expression and subcellular localization of glutaminyl cyclase in mouse brain.
Hartlage-Rübesamen M, Staffa K, Waniek A, Wermann M, Hoffmann T, Cynis H, Schilling St, Demuth H-U, Roßner St.
Int. J. of Dev. Neurosci. 2009, 27, 835-835 (Medline)
Inhibitors for Human Glutaminyl Cyclase by Structure Based Design and Bio-isosteric Replacement.
Buchholz M, Hamann A, Aust S, Brandt W, Böhme L, Hoffmann T, Schilling St, Demuth H-U, Heiser U.
J. Med. Chem. 2009, 52, 7069-7080 (Medline)
Glutaminyl Cyclases Reveal Significant Proficiency for Glutamyl Substrates.
Seifert F, Schulz K, Manhart S, Demuth H-U, Schilling St.
Biochemistry, 2009, 48, 11831-11833 (Medline)